Clinical trial registry record

Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Not Yet Recruiting.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 10, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07342764
Last registry update
June 10, 2026
Status
Not Yet Recruiting
Phase
Phase 4
Sponsor
Sultan Qaboos University
Enrollment
110
Countries
Oman
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
RANDOMIZED · PARALLEL · TREATMENT · SINGLE
Evidence population
Human clinical study registration
Participants
110
Population
ALL · 16 Years to 60 Years
Duration
2026-09-01 to 2028-12-01
Intervention
Dapagliflozin; Metformin; Common Lifestyle Program
Comparator
Metformin
Outcomes measured
Change in Body Weight — Baseline, Week 12, and Week 26 at the maximum tolerated dose; Change in Body Mass Index (BMI) — Baseline, Week 12, and Week 26; Change in Waist Circumference — Baseline, Week 12, and Week 26; Change in Fasting Plasma Glucose — Baseline, Week 12, and Week 26; Change in Glycated Hemoglobin (HbA1c) — Baseline, Week 12, and Week 26; Change in Lipid Profile — Baseline, Week 12, and Week 26; Change in psychiatric symptom severity — Baseline, Week 12, and Week 26; Change in quality of life — Baseline, Week 12, and Week 26; Medication adherence — Week 2, Week 6, Week 12, Week 18, and Week 26; Adverse events and tolerability — Week 2, Week 6, Week 12, Week 18, and Week 26
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Metformin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

metformin
Read the original source →Export JSON